| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/16/2009 | WO2009047770A2 Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases |
| 04/16/2009 | WO2009047766A2 Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| 04/16/2009 | WO2009047762A1 Compositions and peptides for treatment of envenomation by pla2 containing venoms like bungarus multicinct venom |
| 04/16/2009 | WO2009047728A2 New s-acyl-glutathione derivatives, their syntesis and use in the treatment of oxidative stress-related diseases |
| 04/16/2009 | WO2009047513A2 Antagonists of kisspeptin and uses thereof |
| 04/16/2009 | WO2009047330A1 Use of wnt5a for treating or preventing obesity and atherosclerosis |
| 04/16/2009 | WO2009046983A1 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| 04/16/2009 | WO2009046967A1 Aqueous ophthalmic formulations |
| 04/16/2009 | WO2009046881A1 Use of a peptide combination including c-peptide, as a therapeutic agent |
| 04/16/2009 | WO2009046880A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046879A2 Use of the combination of npy and nociceptin as a therapeutic agent |
| 04/16/2009 | WO2009046878A1 Tnf inhibitory peptide and cgrp as therapeutic agents |
| 04/16/2009 | WO2009046877A2 Use of a histrelin and leuprolide as therapeutic agents |
| 04/16/2009 | WO2009046876A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046875A2 Combination of splenopentin and thymopentin and the use thereof in medicine |
| 04/16/2009 | WO2009046874A1 Therapeutic combination of trh-potentiating peptide and stresscopin |
| 04/16/2009 | WO2009046873A1 Combined use of vasonatrin and gastrin-i as a therapeutic agent |
| 04/16/2009 | WO2009046872A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046868A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046867A2 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 04/16/2009 | WO2009046866A2 Trap-14 as a therapeutic agent |
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046851A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046850A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046835A1 Use of goserelin and amylin as therapeutic agents |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046832A2 Short peptides used in medicine |
| 04/16/2009 | WO2009046831A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046830A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046829A2 Casoxin d as a therapeutic agent |
| 04/16/2009 | WO2009046827A2 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents |
| 04/16/2009 | WO2009046826A1 Use of a cyclic penta-peptide as a therapeutic agent |
| 04/16/2009 | WO2009046825A1 Use of a peptide acetyl-calpastatin as a therapeutic agent |
| 04/16/2009 | WO2009046824A2 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis |
| 04/16/2009 | WO2009046823A1 Exendin-3 and apelin-12 for therapeutic applications |
| 04/16/2009 | WO2009046822A2 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 04/16/2009 | WO2009046618A1 Deshydroxy vancomycin, the preparation, pharmaceutical composition and the use |
| 04/16/2009 | WO2009046580A1 The application of the combination of insulin or oral hypoglycemic medicine with raceanisodamine hydrochloride, vitamin b12 and nerve growth factor in the preparation of medicine for treating type ii diabetes |
| 04/16/2009 | WO2009046541A1 MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR |
| 04/16/2009 | WO2009046530A1 Compositions affecting hyaluronic acid mediated activity |
| 04/16/2009 | WO2009046495A1 A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| 04/16/2009 | WO2009046483A1 Therapeutic protocol for the treatment or prevention of thrombocytopenia |
| 04/16/2009 | WO2009026389A3 Regulating glp-1 and sglt-1 in gastrointestinal cells |
| 04/16/2009 | WO2009026334A3 Treatment with kallikrein inhibitors |
| 04/16/2009 | WO2009023846A3 Methods for heat shock protein dependent cancer treatment |
| 04/16/2009 | WO2009021926A3 Use of a neurotoxin |
| 04/16/2009 | WO2009021022A3 Modulating the activity of nuclear receptors in order to treat hypoxia-related disorders |
| 04/16/2009 | WO2009018667A8 Plant bioreactor for the production of interleukin-24 cytokine |
| 04/16/2009 | WO2009017646A3 Compositions comprising human collagen and human elastin and methods for soft tissue augmentation |
| 04/16/2009 | WO2009014702A3 Cd74 for use in the treatment of cancer and liver toxicity |
| 04/16/2009 | WO2009012173A3 Enhanced biotherapeutic production using inhibitory rna |
| 04/16/2009 | WO2009009669A3 Thermostabilization of proteins |
| 04/16/2009 | WO2009007992A3 Pharmaceutical composition produced by microprecipitation |
| 04/16/2009 | WO2009007112A3 Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction |
| 04/16/2009 | WO2008156677A3 Cyclic peptide melanocortin receptor ligands |
| 04/16/2009 | WO2008134090A3 Yeast biocatalysts for degradation of biowarfare agents |
| 04/16/2009 | WO2008133651A3 Ablative immunotherapy |
| 04/16/2009 | WO2008070672A3 Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
| 04/16/2009 | WO2008062431A3 Synergistic anthelmintic composition |
| 04/16/2009 | WO2008048680A3 Notch 2 signaling as a breast cancer suppressor pathway |
| 04/16/2009 | WO2008045696A3 Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases |
| 04/16/2009 | WO2008036717A3 Use of soluble galectin-3 (gal-3) for cancer treatment |
| 04/16/2009 | WO2008033285A3 Delivery of double-stranded rna into the central nervous system |
| 04/16/2009 | WO2008028002A9 Increasing nadph-dependent products |
| 04/16/2009 | WO2008025425A8 Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same |
| 04/16/2009 | WO2008002283A3 Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism |
| 04/16/2009 | WO2007113819A3 Methods and compositions for preventing and treating streptococcus pneumoniae infection |
| 04/16/2009 | WO2007110765A3 Processes for the preparation of octreotide |
| 04/16/2009 | WO2007103368A3 Methods for regulating inflammatory mediators and peptides useful therein |
| 04/16/2009 | WO2007098201A3 Shiga toxoid chimeric proteins |
| 04/16/2009 | WO2007094985A3 Long-acting polypeptides and methods of producing and administering same |
| 04/16/2009 | WO2007092801A3 Methods and compositions for repair of cartilage using an in vivo bioreactor |
| 04/16/2009 | WO2007052154A3 Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| 04/16/2009 | WO2007045955A3 Osteogenic device for inducing bone formation in clinical contexts |
| 04/16/2009 | WO2007030145A3 Elastin protective polyphenolics and methods of using the same |
| 04/16/2009 | WO2007027748A3 C/clp antagonists and methods of use thereof |
| 04/16/2009 | WO2007024817A3 Soluble fibrin inhibitory peptides and uses thereof |
| 04/16/2009 | WO2007015918A3 Novel biologically active peptides and their new uses |
| 04/16/2009 | WO2007008848A3 Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| 04/16/2009 | WO2007008488A3 Stable quantitation and detection of immune response levels with non-zero background peptides |
| 04/16/2009 | WO2007005559A3 Tat-005 and methods of assessing and treating cancer |